

PET Imaging Reveals Early Pulmonary Perfusion Abnormalities in HIV Infection Similar to Smoking

Puja Kohli MD MMSc^{1,2}, Vanessa J Kelly PhD¹, Kathryn A Hibbert MD^{1,2}, Björn Corleis PhD³, Mamary Kone¹, Josalyn Cho MD⁴, Doreen DeFaria-Yeh MD^{2,5}, Douglas S Kwon MD PhD^{2,3,6}, Benjamin Medoff MD^{1,2}, R Scott Harris MD¹, Tilo Winkler PhD⁷

¹Division of Pulmonary and Critical Care at Massachusetts General Hospital, Boston, MA

²Department of Medicine, Harvard Medical School, Boston, MA

³The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA

⁴Department of Internal Medicine and Carver College of Medicine and The University of Iowa, Iowa City, IA

⁵Division of Cardiology, Massachusetts General Hospital, Boston, MA

⁶Division of Infectious Disease, Massachusetts General Hospital, Boston, MA

⁷Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA

Address for Correspondence:

Puja Kohli, MD MMSc

Massachusetts General Hospital/55 Fruit Street, BUL 148, Boston, MA 02114

Email address: pkohli1@mgh.harvard.edu

Fax: 617.726.6878/Telephone number: 617.643.4197

COI: All authors have no relevant conflicts of interest.

Sources of Support: This work was supported by grants to Dr. Ben Medoff NIH 1U01HL121827-01 and Dr. Douglas Kwon 1R01DA042685-01.

Abstract Word Count: 246

Manuscript Word Count: 4998 (including references and figure legends)

Running Title: Early Lung Perfusion Changes in HIV

ABSTRACT

RATIONALE: COPD (Chronic obstructive pulmonary disease) is the most common non-infectious pulmonary disease among people living with HIV, independent of smoking.

However, the cause for this enhanced susceptibility remains unclear, and the effects of HIV on pulmonary perfusion and ventilation are unknown.

METHODS: We used PET-CT in 46 smokers and non-smokers, 23 of whom had documented HIV infection. Emphysema was assessed by CT and perfusion by nitrogen-13 (^{13}N) PET scans. After removal of image noise, vertical and axial gradients in perfusion were calculated. We tested for differences in the total spatial heterogeneity of perfusion ($\text{CV}^2_{\text{Qtotal}}$) and its components ($\text{CV}^2_{\text{Qtotal}} = \text{CV}^2_{\text{Qvgrad}}$ (vertical gradient) + $\text{CV}^2_{\text{Qzgrad}}$ (axial gradient) + CV^2_{Qr} (residual heterogeneity)) among groups.

RESULTS: There were no significant differences in demographic parameters among groups, and all subjects had minimal radiographic evidence of emphysema. Compared to controls, non-smokers living with HIV had a significantly greater $\text{CV}^2_{\text{Qr}}/\text{CV}^2_{\text{Qtotal}}$ (0.48 vs 0.36, $p = 0.05$) and reduced $\text{CV}^2_{\text{Qvgrad}}/\text{CV}^2_{\text{Qtotal}}$ (0.46 vs 0.65, $p = 0.038$). Smokers also had a reduced $\text{CV}^2_{\text{Qvgrad}}/\text{CV}^2_{\text{Qtotal}}$, however, there was no significant difference in $\text{CV}^2_{\text{Qvgrad}}/\text{CV}^2_{\text{Qtotal}}$ between smokers living with and without HIV (0.39 vs 0.34, $p = 0.58$), despite a decreased vertical perfusion gradient (Q_{vgrad}) in smokers living with HIV.

CONCLUSIONS: In non-smokers living with well-controlled HIV and minimal radiographic emphysema, HIV infection contributes to pulmonary perfusion abnormalities similar to smokers. These data indicate the onset of subclinical pulmonary perfusion abnormalities that could herald the development of significant lung disease in these susceptible individuals.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality in individuals living with HIV (1,2). Approximately 20% of individuals living with HIV are estimated to have airflow obstruction (3,4), and although there is a higher prevalence of smoking in patients living with HIV (5), the increased incidence of COPD is out of proportion to what would be expected. Interestingly, nearly 1 in 6 non-smokers living with HIV also have emphysematous changes in their lungs (2), implicating unrecognized mechanisms promoting COPD among those living with HIV. Despite the improved outcomes with antiretroviral therapy (HAART), individuals living with HIV continue to have accelerated development of COPD leading to increased morbidity and mortality (6).

The mechanisms that promote accelerated COPD in HIV infection are incompletely understood. In COPD, regional and systemic inflammation in response to inhaled toxins is thought to cause airway injury and tissue destruction. Dysfunction of the pulmonary vasculature in response to such inflammation has been implicated as a critical event in the pathogenesis of COPD (7,8). *In vitro*, HIV-associated proteins have been shown to induce dysfunctional vasoconstriction, endothelial proliferation and plexiform lesions (9). This suggests that HIV infection induces additional dysfunction of the pulmonary vasculature beyond smoking alone, which may contribute to the development of accelerated COPD compared to individuals without HIV. However, studies assessing the effect of HIV on regional pulmonary blood flow and tissue destruction are lacking. Gaining greater insight into the role of pulmonary perfusion in the pathogenesis of COPD in this population is vital to identifying effective and specific therapeutic targets.

In this study we investigated pulmonary perfusion and ventilation using ^{13}N -saline positron-emission tomography and computed tomography (PET-CT) imaging for quantitative characterization of the spatial distributions of pulmonary perfusion (perfusion heterogeneity) and ventilation (10–13,8), and components of the perfusion heterogeneity, including gradients in the dorsoventral and craniocaudal direction. These gradients are primarily caused by hydrostatic pressure and regional systematic differences in structure or function of the vascular tree. After removing these gradients, the residual heterogeneity in perfusion provides insight into the remaining anatomic and vasoactive variations in pathway resistance. We aim test our hypothesis that chronic HIV infection promotes pulmonary vascular dysfunction manifesting as increased pulmonary perfusion heterogeneity prior to tissue destruction in the lung parenchyma.

METHODS

Subjects

The study was approved by the Institutional Review Board (IRB) of the Massachusetts General Hospital, protocol number 2013P002436. Verbal and signature of written informed consent was obtained from each subject before the study. Inclusion criteria were adult volunteers of either sex, ages 18-65 years of age. Subjects living with HIV were required to have a viral load drawn at the time of enrollment. Subjects enrolled without HIV were required to have a documented HIV negative antibody screening test within the previous 6 months. All subjects were required to have laboratory values within 45 days of enrollment that met the following criteria: hemoglobin $\geq 10\text{g/dL}$, absolute neutrophil count $\geq 1000/\text{mm}^3$, platelet count $\geq 80,000/\text{mm}^3$, prothrombin time (PT) $< 1.5 \times$ upper limit of normal, partial thromboplastin time

(PTT) 1.5 x upper limit of normal and, for female participants, a negative urine pregnancy test (sensitive to 25 IU HCG) at screening and within 24 hours of the study procedures.

All subjects underwent screening spirometry. Patients were eligible for participation in the study if pulmonary function was within normal limits ($FEV_1/FVC > 0.7$) or revealed GOLD I ($FEV_1/FVC < 0.7$ and $FEV_1 \geq 80\%$ predicted) or GOLD II ($FEV_1/FVC < 0.7$ and $\geq 50\%$ and $< 80\%$ predicted) obstructive airways disease.

Exclusion criteria included any female subjects who were pregnant or less than 3 months post-partum, any history of coronary artery disease, myocardial infarction, chronic renal insufficiency, decompensated cirrhosis and intolerance and/or allergy to ester type anaesthetics, benzodiazepines or opiates. Medication use exclusions included any subjects taking anticoagulants or antiplatelet agents that could not be stopped for at least 1 week, systemic steroids, interleukins, systemic interferons, systemic chemotherapy, immunomodulatory agents or antibiotic therapy within 30 days prior to study enrollment, and any prior receipt of the HIV vaccine.

Subjects living with HIV receiving HAART as part of their treatment were maintained on those therapies on the day of study.

Functional Imaging of Pulmonary Perfusion and Ventilation

Subjects were positioned supine and with arms abducted on the table of the PET-CT scanner (Biograph 64, Siemens Healthcare, Malvern PA, USA). Relative lung volume was continuously measured using impedance plethysmography (SomnoStar PT, SensorMedics Corp., Yorba Linda, CA, USA). After calibration of plethysmograph, mean lung volume (MLV) was

determined during 30 seconds of steady tidal breathing prior to imaging. We then acquired ‘topogram’ CT scan to determine the field of view for PET and for CT scans. In preparation for a CT scan, the subject was asked to inhale to total lung capacity (TLC), followed by slow exhalation to MLV, and to hold their breath for <10 seconds while the CT scan was acquired. Following this, a dynamic ^{13}N PET scan was acquired (14) starting with a 30-second breath-hold at MLV. Radiation doses for all subjects ranged from 3.1- 3.5 mSv.

Perfusion and ventilation images were generated from the ^{13}N -saline PET scan, using a tracer kinetics analysis that has been described previously (14,15). Briefly, nitrogen has a very low solubility in blood so that ^{13}N diffuses during its passage through the pulmonary capillaries rapidly out of the blood into the alveolar gas space, where it accumulates during the breath hold reaching a plateau that is directly proportional to the relative perfusion. Thus, ^{13}N PET images of the plateau activity normalized by the mean of the entire lung are images of relative perfusion. After the breath hold, the subject resumes tidal breathing, which results in a washout of the ^{13}N by ventilation with a washout rate proportional to the specific ventilation (sV) of the voxel: $sV = \text{alveolar ventilation } (V_A) / \text{alveolar volume}$.

The degree of lung inflation was quantified as the fraction of gas content (F_{gas}). Specifically, Hounsfield Units (HU) of CT scans were converted to F_{gas} using $F_{\text{gas}} = (\text{tissue density} - \text{density value of the voxel}) / (\text{tissue density} - \text{density of air})$ where tissue density = 0 HU and density of gas = -1000 HU. Tissue fraction (F_{tis}) images were calculated using $F_{\text{tis}} = 1 - F_{\text{gas}}$.

Perfusion Heterogeneity

Heterogeneity of different parameters were quantified as the square of the coefficient of variation ($CV^2 = (\text{standard deviation} / \text{mean})^2$) (13). Relative perfusion images were used to

calculate total spatial heterogeneity of perfusion (CV^2_{Qtotal}). The CV^2_{Qtotal} was then separated into components caused by systematic gradients in the vertical (dorsoventral) direction (CV^2_{Qvgrad}), the axial (craniocaudal) direction (CV^2_{Qzgrad}), and the remaining, or residual heterogeneity (CV^2_{Qr}), such that $CV^2_{Qtotal} = CV^2_{Qvgrad} + CV^2_{Qzgrad} + CV^2_{Qr}$.

Ventilation Heterogeneity

^{13}N washout rates were used to calculate the heterogeneity of ventilation (CV^2_{sv}). Since imaging noise cannot be removed from CV^2_{sv} , we did not separate CV^2_{sv} into its components (13).

Statistical Analysis

Our primary outcomes of interest were total spatial heterogeneity of perfusion (CV^2_{Qtotal}) and its components. In secondary analyses, we assessed various regional perfusion, ventilation, and composite metrics. We first implemented the Kruskal-Wallis nonparametric test of variance to test whether there was a difference in rank order of each metric across the study groups: controls (non-smokers without HIV infection), non-smokers living with HIV, smokers without HIV infection and smokers living with HIV. For comparisons attaining $p < 0.05$, we performed specific comparisons between individual groups by Wilcoxon rank sum. Multiple-hypothesis testing correction was performed using Tukey-Kramer method (SAS for Windows, version 9.4; SAS Institute Inc., Cary, NC, USA). For secondary and exploratory correlation analyses, spearman rank-order correlations were performed. Statistical significance was set at $p < 0.05$. Data are presented as mean (standard deviation) unless otherwise stated.

RESULTS

Subjects

General clinical characteristics of the subjects are presented in Table 1 and physiologic characteristics in Table 2. All subjects living with HIV had viral loads < 90, and all but 3 (designated as elite controllers) were on HAART. All smokers reported > 10 pack years of smoking. Controls were younger and included more female participants than the other groups. (Table 1) There were no significant differences in spirometry between groups. (Table 2)

Regional Perfusion Distribution

The total heterogeneity of perfusion ($CV^2_{Q_{total}}$) was not different among groups ($p_{kw} = 0.59$). (Fig. 1) However, the components of $CV^2_{Q_{total}}$ ($CV^2_{Q_{vgrad}}$, $CV^2_{Q_{zgrad}}$, $CV^2_{Q_r}$) distinguished the groups. (Table 3, Fig. 2) Despite a younger mean age in the control group, age was not associated with any of these primary outcome measures within the control group.

Among non-smokers, subjects living with HIV had a significantly lower contribution of the vertical perfusion gradient ($CV^2_{Q_{vgrad}}/CV^2_{Q_{total}}$) than controls (0.46 vs 0.65, $p = 0.038$), approaching values similar to those seen in smokers. (Table 3, Fig. 2). Current smokers had a significantly smaller $CV^2_{Q_{vgrad}}/CV^2_{Q_{total}}$ than non-smokers (0.36 vs 0.6, $p = 0.002$). However, among smokers, there was no significant difference in $CV^2_{Q_{vgrad}}/CV^2_{Q_{total}}$ between those living with and without HIV infection (0.39 vs 0.34, $p = 0.58$).

The median slope of the vertical gradient of perfusion (Q_{vgrad}) demonstrated a stepwise decrement from controls (-6.96 +/- 1.31) to non-smokers living with HIV (-5.32 +/- 1.83 $10^{-2}cm^{-1}$) to smokers without HIV infection (-4.88 +/- 1.79 $10^{-2}cm^{-1}$) to smokers living with HIV (-4.7 +/- 1.66 $10^{-2}cm^{-1}$). All groups demonstrated significantly lower Q_{vgrad} than controls ($p_{kw} = 0.003$). (Table 3, Fig. 3 and Supplement Fig. E1) Notably, 11 of 13 (85%) of subjects with a Q_{vgrad} below the range of controls were subjects living with HIV. (Fig. 4)

The contribution of the residual heterogeneity to total heterogeneity of perfusion (CV^2_{Qr}/CV^2_{Qtotal}) was higher in all groups compared to the control group ($p_{kw}= 0.01$). Non-smokers living with HIV demonstrated a similar residual perfusion heterogeneity as smokers ($p=0.41$). Smokers had similar CV^2_{Qr} regardless of HIV status ($p = 0.65$). (Table 3, Fig. 2)

Regional Ventilation Distribution

Lung parenchymal density (estimated by F_{tis}) was similar across all groups. However, the slope of the vertical gradient of specific ventilation (sV_{grad}) was nonsignificantly lower in all groups compared to controls ($p_{kw} = 0.09$). There was a stepwise decline in sV_{grad} when comparing non-smokers living with HIV to smokers without HIV infection to smokers living with HIV, with smokers living with HIV having the lowest sV_{grad} compared to their counterparts. (Supplemental Table E1)

Compared to controls, the heterogeneity of specific ventilation (CV^2_{sv}) was greater in non-smokers living with HIV and smokers without HIV infection, following a pattern similar to, although not strongly correlated with, the residual heterogeneity in perfusion (CV^2_{sv} vs CV^2_{Qr} , $r=0.43$, $p = 0.003$). CV^2_{sv} was also not strongly correlated with the total heterogeneity of perfusion (CV^2_{Qtotal}) ($r = 0.26$, $p = 0.08$). (Fig. 5, Supplemental Table E1)

Ventilation-Perfusion Distribution

The distributions of V/Q ratios did not distinguish subjects based on HIV infection or smoking status. The distributions were unimodal in all subjects, except 2 control subjects and 1 smoker living with HIV who had bimodal distributions. (Supplemental Table E2 and Supplemental Fig. E2)

DISCUSSION

We performed functional ^{13}N PET imaging on 46 subjects to characterize early subclinical pulmonary perfusion abnormalities in the setting of HIV infection and smoking. This study had two major findings: 1. among non-smokers, subjects living with HIV infection had an increased residual perfusion heterogeneity with a diminished dorsoventral perfusion gradient, approaching values similar to smokers, 2. among smokers, living with HIV infection led to a further reduction in the mean slope of the vertical gradient of perfusion. These results permit several conclusions. Controlled HIV infection alone or associated factors such as HAART promote subclinical abnormalities in pulmonary perfusion analogous to smoking that are identified by pulmonary perfusion imaging. Amongst smokers, controlled HIV infection further contributes to the development of early perfusion abnormalities. These perfusion findings in smokers and patients living with HIV may precede the development of overt lung disease, providing novel screening metrics for early disease and targets for potential therapeutic modulation to prevent possible progression of disease.

Lung diseases among persons living with HIV are more common than in the general population and remain leading causes of morbidity and mortality despite successful HAART treatment. The central role of dysfunctional immune activation and augmented inflammation in driving the pathogenesis of non-AIDS-defining conditions has been studied and established, although not as clearly in the lung (6,16,17). Although HIV has not been shown to directly infect pulmonary vascular endothelial cells (18,19), there are many possible pathways for HIV infection to cause vascular dysfunction such as those found in the non-smokers living with HIV in our study. For instance, HIV viral antigens present in the pulmonary endothelium may directly stimulate abnormal growth and proliferation causing vascular dysfunction (18,20).

Additionally, the chronic inflammatory state and persistent immune activation and dysregulation in HIV infection could induce the release of proinflammatory cytokines that have been invoked in the development of pulmonary vasculopathies (21). Finally, although it is unknown how HIV infection affects the vasculature of the bronchial circulation, HIV may promote leukocyte emigration via the bronchial circulation (22) or cause bronchial vessel remodeling contributing airway wall changes (23), similar to the effects of smoking related vascular changes in the development of COPD.

These regional perfusion abnormalities in nonsmoking patients living with HIV are similar to smoking patients indicating that the vascular dysfunction caused by HIV infection alone may contribute to the development of emphysema in this population. Our data showing nearly all subjects regardless of smoking status with a vertical perfusion gradient attenuated below the range of controls were living with HIV (Fig. 4), is additional evidence that the vascular dysfunction caused by HIV infection may be crucial to the enhanced emphysema susceptibility seen in individuals living with HIV. Further longitudinal study is required to test this hypothesis.

In our study, smokers, regardless of HIV infection, also demonstrated significantly reduced vertical gradients in perfusion and greater residual perfusion heterogeneity compared to controls. Hypoxic pulmonary vasoconstriction (HPV) is normally blocked by inflammation maintaining perfusion in inflamed areas (24,25). In animals exposed to tobacco smoke, however, pulmonary vascular abnormalities cause ongoing vasoconstriction and precede emphysema development (26–28). Using functional imaging, our group and others demonstrated perfusion heterogeneity in smokers with early emphysema susceptibility (8,29). The inability of smokers to maintain perfusion in inflamed regions due to failure to block HPV

(ongoing vasoconstriction) may be the critical event in the pathogenesis of emphysema (7,30). Our study supports these prior findings showing increased residual perfusion heterogeneity in smokers.

In smokers living with HIV, the vertical gradient in perfusion was severely reduced, likely due to early but increasing pulmonary vascular pressures counteracting the effects of hydrostatic pressure. Our study did not find a significant difference in regional pulmonary perfusion between smokers living with and without HIV infection. Inflammation and oxidative stress from smoking alone may cause perfusion changes beyond any additive immune dysfunction of HIV infection in the smoking group. However, we also observed a decremental trend towards loss of the vertical gradient in perfusion from non-smokers living with HIV ($-5.32 \pm 1.83 \text{ } 10^{-2} \text{ cm}^{-1}$) to smokers without HIV infection ($-4.88 \pm 1.79 \text{ } 10^{-2} \text{ cm}^{-1}$) to smokers living with HIV ($-4.7 \pm 1.66 \text{ } 10^{-2} \text{ cm}^{-1}$).

As half of our cohort underwent echocardiography with normal results, our results reveal that perfusion imaging can detect much earlier stages of pulmonary vascular dysfunction, such as changes in the gradients of perfusion, compared with current conventional noninvasive methods of assessment. Also, our results showing increased residual perfusion heterogeneity and a diminished vertical gradient in perfusion in all non-smokers living with HIV (Fig. 2), indicate that HIV-associated pulmonary vascular dysfunction may be more common than previously recognized. However, it is not possible to determine with certainty if the perfusion abnormalities we have found are a primary defect or secondary to ventilation abnormalities.

Limitations of the ^{13}N imaging technique have been discussed in detail (14,15) including the lower resolution of PET scans compared to CT or MRI scans. However, the ^{13}N -bolus

method allows functional imaging of both pulmonary perfusion and specific ventilation using a single injection . ^{13}N tracer kinetics and image misalignments can affect the accuracy of noise-free CV^2_{Q} parameters. However, such errors occurring randomly should only diminish differences among groups and bias results towards the null hypothesis of statistical tests. Finally, despite notable differences observed with our current sample size, future studies in larger sample sizes followed longitudinally are required.

CONCLUSIONS

In subjects with well-controlled HIV and minimal radiographic emphysema, both HIV infection and smoking are associated with an increased fraction of residual perfusion heterogeneity and a reduction in the vertical gradient of perfusion. These findings may precede the development of overt lung disease, which represents an opportunity for earlier risk prediction, preventive strategies and alternate therapeutic targets.

ACKNOWLEDGEMENTS

The authors thank the staff from the Massachusetts General Hospital Departments of Nuclear Medicine and Nuclear Pharmacy for their assistance with this project, including Steve Weise, Michael Cournoyer, John Correia, Eugene Lee, Peter Rice, Melissa Bruen, Erin Beloin, Kevin Vernon and Daniel Yokell. In addition, the authors extend kind thanks to the staff at the Ragon Institute for their assistance with recruitment and Rebecca Harris for her contributions to mask creation.

KEY POINTS

QUESTION: Does chronic HIV infection promote pulmonary vascular dysfunction manifesting as increased pulmonary perfusion heterogeneity prior to tissue destruction (emphysema) in the lung parenchyma?

PERTINENT FINDINGS: In a study of 46 smokers and nonsmokers living with and without HIV who underwent CT and nitrogen-13 (^{13}N) PET scans, non-smokers living with HIV had a significantly greater perfusion heterogeneity and reduced vertical gradient of perfusion compared to controls. These perfusion abnormalities were similar to smokers.

IMPLICATIONS FOR PATIENT CARE: These data indicate the onset of subclinical pulmonary perfusion abnormalities that may herald the development of significant lung disease in individuals living with HIV.


References

1. Drummond MB, Kirk GD. HIV-associated obstructive lung diseases: insights and implications for the clinician. *Lancet Respir Med.* 2014;2:583-592.
2. Morris A, George MP, Crothers K, et al. HIV and chronic obstructive pulmonary disease: is it worse and why? *Proc Am Thorac Soc.* 2011;8:320-325.
3. Gingo MR, Morris A. Pathogenesis of HIV and the lung. *Curr HIV/AIDS Rep.* 2013;10:42-50.
4. Raynaud C, Roche N, Chouaid C. Interactions between HIV infection and chronic obstructive pulmonary disease: Clinical and epidemiological aspects. *Respir Res.* 2011;12:117.
5. Marshall MM, McCormack MC, Kirk GD. Effect of cigarette smoking on HIV acquisition, progression, and mortality. *AIDS Educ Prev Off Publ Int Soc AIDS Educ.* 2009;21:28-39.
6. Plaeger SF, Collins BS, Musib R, Deeks SG, Read S, Embry A. Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary. *AIDS Res Hum Retroviruses.* 2012;28:469-477.
7. Iyer KS, Newell JD, Jin D, et al. Quantitative Dual-Energy Computed Tomography Supports a Vascular Etiology of Smoking-induced Inflammatory Lung Disease. *Am J Respir Crit Care Med.* 2015;193:652-661.
8. Vidal Melo MF, Winkler T, Harris RS, Musch G, Greene RE, Venegas JG. Spatial heterogeneity of lung perfusion assessed with (13)N PET as a vascular biomarker in chronic obstructive pulmonary disease. *J Nucl Med Off Publ Soc Nucl Med.* 2010;51:57-65.
9. Bigna JJR, Sime PSD, Koulla-Shiro S. HIV related pulmonary arterial hypertension: epidemiology in Africa, pathophysiology, and role of antiretroviral treatment. *AIDS Res Ther.* 2015;12:36.
10. Harris RS, Winkler T, Tgavalekos N, et al. Regional pulmonary perfusion, inflation, and ventilation defects in bronchoconstricted patients with asthma. *Am J Respir Crit Care Med.* 2006;174:245-253.
11. Harris RS, Winkler T, Musch G, et al. The prone position results in smaller ventilation defects during bronchoconstriction in asthma. *J Appl Physiol Bethesda Md 1985.* 2009;107:266-274.
12. Kelly VJ, Hibbert KA, Kohli P, et al. Hypoxic Pulmonary Vasoconstriction Does Not Explain All Regional Perfusion Redistribution in Asthma. *Am J Respir Crit Care Med.* June 2017.

13. Winkler T, Melo MFV, Degani-Costa LH, et al. Estimation of noise-free variance to measure heterogeneity. *PLoS One*. 2015;10:e0123417.
14. Melo MFV, Layfield D, Harris RS, et al. Quantification of Regional Ventilation-Perfusion Ratios with PET. *J Nucl Med*. 2003;44:1982-1991.
15. Musch G, Layfield JDH, Harris RS, et al. Topographical distribution of pulmonary perfusion and ventilation, assessed by PET in supine and prone humans. *J Appl Physiol Bethesda Md* 1985. 2002;93:1841-1851.
16. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. *Immunity*. 2013;39:633-645.
17. Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. *Immunol Rev*. 2013;254:326-342.
18. Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. *Biochem Biophys Res Commun*. 2005;333:1107-1115.
19. Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. *Eur Respir J*. 1998;11:554-559.
20. Mermis J, Gu H, Xue B, et al. Hypoxia-inducible factor-1 α /platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling. *Respir Res*. 2011;12:103.
21. Morse JH, Barst RJ, Itescu S, et al. Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles. *Am J Respir Crit Care Med*. 1996;153:1299-1301.
22. Davis BB, Shen Y-H, Tancredi DJ, Flores V, Davis RP, Pinkerton KE. Leukocytes are recruited through the bronchial circulation to the lung in a spontaneously hypertensive rat model of COPD. *PLoS One*. 2012;7:e33304.
23. Hashimoto M, Tanaka H, Abe S. Quantitative analysis of bronchial wall vascularity in the medium and small airways of patients with asthma and COPD. *Chest*. 2005;127:965-972.
24. Schuster DP, Marklin GF. The effect of regional lung injury or alveolar hypoxia on pulmonary blood flow and lung water measured by positron emission tomography. *Am Rev Respir Dis*. 1986;133:1037-1042.
25. Gust R, Kozlowski J, Stephenson AH, Schuster DP. Synergistic hemodynamic effects of low-dose endotoxin and acute lung injury. *Am J Respir Crit Care Med*. 1998;157:1919-1926.
26. Wright JL, Churg A. Advances in the pathology of COPD. *Histopathology*. 2006;49:1-9.


27. Seimetz M, Parajuli N, Pichl A, et al. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. *Cell*. 2011;147:293-305.
28. Ferrer E, Peinado VI, Castañeda J, et al. Effects of cigarette smoke and hypoxia on pulmonary circulation in the guinea pig. *Eur Respir J*. 2011;38:617-627.
29. Alford SK, van Beek EJR, McLennan G, Hoffman EA. Heterogeneity of pulmonary perfusion as a mechanistic image-based phenotype in emphysema susceptible smokers. *Proc Natl Acad Sci U S A*. 2010;107:7485-7490.
30. Hueper K, Vogel-Claussen J, Parikh MA, et al. Pulmonary Microvascular Blood Flow in Mild Chronic Obstructive Pulmonary Disease and Emphysema. The MESA COPD Study. *Am J Respir Crit Care Med*. 2015;192:570-580.

Figure 1:



Total perfusion heterogeneity excluding imaging noise (CV^2_{Qtotal}) was not different among controls, non-smokers living with HIV, smokers without HIV infection, and smokers living with HIV. The boxplots include the median and the 25th and 75th percentiles of each group.


Figure 2:



Components of perfusion heterogeneity revealed non-smokers living with HIV have similar spatial perfusion abnormalities as smokers. Components normalized by the total spatial heterogeneity of perfusion (CV^2_{Qtotal}) show that smokers, regardless of HIV infection, demonstrated an increased contribution of residual perfusion heterogeneity (CV^2_{Qr}/CV^2_{Qtotal}) (A)


with a significantly diminished contribution of the vertical perfusion gradient ($CV^2_{Qvgrad}/CV^2_{Qtotal}$) (**B**) as compared to controls. There was no significant difference in the axial gradient ($CV^2_{Qzgrad}/CV^2_{Qtotal}$) among groups (**C**). Non-smokers living with HIV exhibited a similar pattern with values of high CV^2_{Qr}/CV^2_{Qtotal} and reduced $CV^2_{Qvgrad}/CV^2_{Qtotal}$ approaching that of smokers as shown by the mean values of the component contributions (**D**). A-C: significant differences in mean values are marked underneath the box plots (* $p < 0.05$). D: the letters A-C correspond to the components of heterogeneity in the panels above.

Figure 3:




The slope of the vertical gradient in perfusion was attenuated with HIV infection and smoking. Representative axial slices of the PET perfusion images (upper row) and height versus mean-normalized perfusion plots (lower row) are presented for the individual from each group who had the median vertical gradient in perfusion (Q_{vgrad}). Note, the vertical gradient in perfusion was significantly greater (more negative slope) in controls as compared to the other groups ($p_{anova}=0.003$), and there was a stepwise decrement from controls to non-smokers living with HIV, to smokers without HIV infection, to smokers living with HIV.

Figure 4:



Subjects with vertical perfusion gradients below the range of controls were those living with HIV. The slope of the vertical gradient of perfusion (Q_{vgrad}) correlated with CV^2_{Qtotal} ($r = 0.53$, $p = 0.0002$) (**A**), given a more negative Q_{vgrad} (greater slope) contributes to greater perfusion heterogeneity. Q_{vgrad} also demonstrated a stepwise decrement from controls to smokers living with HIV (**B**) with significant differences from controls (* $p < 0.05$). Notably, the majority of subjects with a Q_{vgrad} below the range of controls (closed black circles) were subjects living with HIV except two noninfected smokers. The dotted line marks the lowest vertical perfusion gradient of the controls. Note, each data point in panel A corresponds to a data point with the same Q_{vgrad} in panel B.

Figure 5:



Heterogeneity of specific ventilation (CV^2_{sv}) was not closely correlated with perfusion heterogeneity (CV^2_{Qtotal}) ($r=0.26$, $p=0.08$) (A). However, there were some significant differences among groups ($* p < 0.05$) (B), following a pattern similar to, although not strongly correlated with, the residual heterogeneity in perfusion (CV^2_{sv} vs CV^2_{Qr} , $r=0.43$, $p=0.003$). Note, each data point in panel A corresponds to a data point with the same CV^2_{sv} in panel B.

Tables

Table 1: Baseline Clinical Characteristics

Trait	Non-smoker		Smoker		p _{kw} -value
	HIV-	HIV+	HIV-	HIV+	
n	15	11	7	12	
Age, mean (SD)	37 (16)	52 (9)	51 (7)	51 (8)	0.002
Race, White	10 (66.7%)	8 (72.7%)	5 (71.4%)	4 (33.3%)	0.10
Sex, Female	8 (53.3%)	1 (9.1%)	1 (14.3%)	2 (16.7%)	0.04
BMI (SD)	25.8 (3.7)	26.7 (2.6)	24.5 (3.2)	26.9 (2.8)	0.37
Pack Years (SD)	0	0	16.3 (11.4)	12.8 (7.2)	
Prior smokers, < 5 pack yrs	5 (33.3%)	5 (45.5%)	0	0	
Current HAART	0	9 (81.8%)	0	11 (91.7%)	
Viral Load	0	<40	0	<90	

Continuous variables are represented as mean (SD) and categorical variables are represented as counts (proportions).

Definitions: BMI = body mass index; HAART = highly active antiretroviral therapy.

Table 2 Baseline Physiologic Characteristics

Trait	Non-smoker		Smoker		p _{kw} -value
	HIV-	HIV+	HIV-	HIV+	
*%HU950_{MLV}	1.51 (2.5)	1.53 (1.94)	1.5 (1.17)	1.31 (1.82)	0.99
*%HU910_{MLV}	5.89 (11.36)	3.55 (2.44)	5.94 (4.45)	2.46 (2.02)	0.56
PASP (range)	31.71 (25-39)	35.25 (30-40)	31.45 (23-44)	33.81 (32-37)	0.76
FEV₁	3.62 (0.72)	3.61 (0.53)	3.37 (0.68)	3.34 (0.81)	0.66
FEV₁, %predicted	100.45 (16.05)	94.83 (16.8)	105.92 (25.96)	107.11 (13.73)	0.36
FVC	4.52 (0.85)	4.43 (0.70)	4.24 (0.85)	4.1 (0.99)	0.62
FVC, % predicted	102.38 (14.52)	98.31 (14.70)	108 (24.61)	113.39 (13.32)	0.14

Continuous variables are represented as mean (SD).

* Measurement of Hounsfield units at MLV likely underestimate the amount of emphysema typically measured at TLC.

Definitions: %HU950_{MLV} = percent of voxels with measured Hounsfield units < -950 at MLV;

%HU910_{MLV} = percent of voxels with measured Hounsfield units < -910 at MLV; FEV₁ = forced expiratory volume in first second; FVC= forced vital capacity.

Table 3: Regional Perfusion Distribution

Trait	Non-smoker		Smoker		p _{kw} -value
	HIV-	HIV+	HIV-	HIV+	
Q_{vgrad} (10⁻²cm⁻¹)	6.96 (1.31)*†‡	5.32 (1.83)‡	4.88 (1.79)†	4.7 (1.66)*	0.003
CV²_{Qtotal}	0.12 (0.04)	0.12 (0.05)	0.13 (0.05)	0.1 (0.06)	0.59
CV²_{Qvgrad}/ CV²_{Qtotal}	0.65 (0.13)*†‡	0.46 (0.19)‡	0.34 (0.17)†	0.39 (0.16)*	0.002
CV²_{Qzgrad}/ CV²_{Qtotal}	0.04 (0.05)	0.07 (0.08)	0.11 (0.13)	0.1 (0.13)	0.23
CV²_{Qr}/ CV²_{Qtotal}	0.36 (0.13)*†‡	0.48 (0.15)‡	0.54 (0.15)†	0.51 (0.13)*	0.013

Variables are represented as mean (SD).

*†‡ indicate p value < 0.05 in with Wilcoxon rank sum testing